Physician profile
Ramona Parkash
NPI 1477395705
$2,187.63
in general payments reported to CMS, 2019-2025
15 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $827 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.77 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407.13 | 2024-2025 | |
| Incyte Corporation | $305.67 | 2024-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $250.95 | 2024-2025 | Tremfya |
| Pfizer INC. | $249.03 | 2024-2025 | |
| Galderma Laboratories, L.P. | $192.03 | 2025 | Nemluvio |
| Amgen INC. | $140.97 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $108.61 | 2024 | Dupixent |
| Genzyme Corporation | $107.39 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $96.28 | 2025 | Sotyktu |
| Lilly USA, LLC | $93.96 | 2024-2025 | Ebglyss, Taltz |
| Sun Pharmaceutical Industries INC. | $84.67 | 2024-2025 | |
| Ucb, INC. | $77.72 | 2025 | Bimzelx |
| Leo Pharma INC. | $28.12 | 2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $24.64 | 2025 | |
| Organon LLC | $20.46 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Parkash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.